Halozyme Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2014. Amounts below are in millions of dollars unless noted. The company is a biopharmaceutical business focused on its rHuPH20 enzyme technology, developing proprietary candidates and partnering with drugmakers. Hylenex recombinant was its only marketed proprietary product.
Financial performance
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Total revenue | $18.4 | $14.5 | $30.4 | $26.3 |
| Operating loss | $(14.9) | $(22.1) | $(40.2) | $(40.6) |
| Net loss | $(16.3) | $(22.9) | $(42.8) | $(42.2) |
| Net loss per share, basic and diluted | $(0.13) | $(0.20) | $(0.35) | $(0.38) |
| Research and development expense | $18.6 | $28.0 | $40.1 | $50.0 |
| Selling, general and administrative expense | $8.8 | $7.3 | $19.0 | $14.9 |
- Q2 product sales were $9.5 million, including $6.0 million of bulk rHuPH20 supplied for Roche products; Hylenex sales were $3.0 million. Royalties were $1.7 million, primarily on Roche’s Herceptin SC sales. Collaborative-agreement revenue was $7.2 million.
- For the first half, product sales were $18.1 million, royalties $2.5 million, and collaborative-agreement revenue $9.8 million. The $13.5 million increase in product sales primarily reflected $11.9 million of Roche-related bulk enzyme sales and higher Hylenex sales.
- Operating losses narrowed in Q2, while first-half net loss was slightly higher year over year. Lower R&D expense reflected, in part, reduced collaboration manufacturing expense and capitalization of approved-product manufacturing costs as inventory. PEGPH20 R&D increased with Study 202 activity. SG&A and interest expense rose.
- Net cash used in operating activities was $33.4 million in the first half, versus $21.7 million a year earlier. Investing activities used $49.1 million; financing provided $111.2 million, principally from the February share offering.
Liquidity, debt and capital
- At June 30, cash and cash equivalents were $56.1 million and available-for-sale marketable securities were $91.5 million, totaling $147.6 million. Current assets were $175.6 million and current liabilities $31.7 million.
- Total debt carrying value was approximately $49.8 million, including $6.2 million current and $43.6 million long-term. The term loan bears 7.55% interest, matures January 2018, and includes a $4.25 million final payment. Principal payments were scheduled to begin in February 2015. The company reported compliance with material loan covenants.
- Stockholders’ equity was $55.3 million, compared with a deficit of $20.0 million at year-end 2013. In February 2014, the company raised $107.7 million net from an underwritten offering of 8.85 million shares at $13 per share.
Developments, outlook and key risks
- Management stated that available cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months. Excluding the February offering proceeds, it projected 2014 net cash burn of approximately $45–$55 million, depending on program progress, manufacturing scale-up, collaboration milestones and royalties, and potential new collaborations. This is a cash-use estimate, not earnings guidance.
- Roche launched MabThera SC in Europe in June, triggering a $5 million sales-based payment due in July. Because of continuing involvement obligations, the payment was to be deferred and recognized over the collaboration term. Herceptin SC was already launched in Europe. Baxter’s HyQvia had European authorization; following a July 31, 2014 FDA advisory committee vote favoring its benefit-risk profile, FDA review of Baxter’s amended application remained pending. These are developments after quarter-end.
- PEGPH20 Study 202 was temporarily halted in April after a possible difference in thromboembolic events between treatment groups. The FDA allowed the trial to continue under a revised protocol in June; enrollment and dosing resumed in July with risk exclusions and anticoagulant prophylaxis. A related cooperative-group study remained on hold pending protocol discussions.
- Hylenex’s Phase 3 CONSISTENT 1 trial met its six-month A1C non-inferiority endpoint. The company was still discussing with FDA the requirements for a label update to support promotion for insulin-pump use; approval and commercial feasibility were uncertain.
- ViroPharma and Intrexon collaborations were terminated effective May 2014. HyQvia and prior Cinryze development raised continuing questions about anti-rHuPH20 antibodies, though the filing reported no associated adverse events in those programs.
- Key business risks include clinical and regulatory setbacks, safety signals, dependence on collaborators and contract manufacturers, uncertain product adoption and revenue timing, sustained operating losses, potential need for further financing and dilution, and debt covenant/default risk. The company reported no material legal proceeding and no material change in market risk; disclosure controls were assessed as effective.
Investor verification points
- Track Study 202 safety data and enrollment under the revised PEGPH20 protocol, and the status of the related SWOG study.
- Confirm FDA action and timing on Baxter’s HyQvia application and any implications of anti-rHuPH20 antibodies.
- Verify progress toward an FDA-supported Hylenex label update for insulin-pump use and the commercial case for that indication.
- Monitor Roche and Baxter product launches, sales, royalties, milestones and the resulting variability in collaboration revenue.
- Compare actual cash burn with management’s $45–$55 million 2014 estimate and assess liquidity, future financing needs, share dilution and debt obligations.